India, July 15 -- image credit- shutterstock

Hyderabad-based Aurobindo Pharma has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only.

This enables Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months.

K. Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo Pharma said,"We are ...